Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F24%3A10477964" target="_blank" >RIV/00216208:11130/24:10477964 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/24:10477964 RIV/00064203:_____/24:10477964 RIV/00064165:_____/24:10477964
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=AK6ok7nWgV" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=AK6ok7nWgV</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00432-024-05628-2" target="_blank" >10.1007/s00432-024-05628-2</a>
Alternative languages
Result language
angličtina
Original language name
Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors
Original language description
PURPOSE: Immune checkpoint inhibitors (ICIs) dramatically changed the prognosis of patients with NSCLC. Unfortunately, a reliable predictive biomarker is still missing. Commonly used biomarkers, such as PD-L1, MSI, or TMB, are not quite accurate in predicting ICI efficacy. METHODS: In this prospective observational cohort study, we investigated the predictive role of erythrocytes, thrombocytes, innate and adaptive immune cells, complement proteins (C3, C4), and cytokines from peripheral blood of 224 patients with stage III/IV NSCLC treated with ICI alone (pembrolizumab, nivolumab, and atezolizumab) or in combination (nivolumab + ipilimumab) with chemotherapy. These values were analyzed for associations with the response to the treatment and survival endpoints. RESULTS: Higher baseline Tregs, MPV, hemoglobin, and lower monocyte levels were associated with favorable PFS and OS. Moreover, increased baseline basophils and lower levels of C3 predicted significantly improved PFS. The levels of the baseline immature granulocytes, C3, and monocytes were significantly associated with the occurrence of partial regression at the first restaging. Multiple studied parameters (n = 9) were related to PFS benefit at the time of first restaging as compared to baseline values. In addition, PFS nonbenefit group showed a decrease in lymphocyte count after three months of therapy. The OS benefit was associated with higher levels of lymphocytes, erythrocytes, hemoglobin, MCV, and MPV, and a lower value of NLR after three months of treatment. CONCLUSION: Our work suggests that parameters from peripheral venous blood may be potential biomarkers in NSCLC patients on ICI. The baseline values of Tregs, C3, monocytes, and MPV are especially recommended for further investigation.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/NV19-03-00179" target="_blank" >NV19-03-00179: Fecal microbiota transplantation in cancer patients treated with checkpoint inhibitor therapy.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Cancer Research and Clinical Oncology
ISSN
0171-5216
e-ISSN
1432-1335
Volume of the periodical
150
Issue of the periodical within the volume
2
Country of publishing house
DE - GERMANY
Number of pages
13
Pages from-to
99
UT code for WoS article
001171646100002
EID of the result in the Scopus database
2-s2.0-85185690509